ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee von Keilholz, U., Ascierto, P.A., Dummer, R., Robert, C., Lorigan, P., van Akkooi, A., Arance, A., Blank, C.U., Chiarion Sileni, V., Donia, M., Faries, M.B., Gaudy-Marqueste, C., Gogas, H., Grob, J.J., Guckenberger, M., Haanen, J., Hayes, A.J., Hoeller, C., Lebbé, C., Lugowska, I., Mandalà, M., Márquez-Rodas, I., Nathan, P., Neyns, B., Olofsson Bagge, R., Puig, S., Rutkowski, P., Schilling, B., Sondak, V.K., Tawbi, H., Testori, A., Michielin, O.

Volltext

ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee von Michielin, O., van Akkooi, A., Lorigan, P., Ascierto, P.A., Dummer, R., Robert, C., Arance, A., Blank, C.U., Chiarion Sileni, V., Donia, M., Faries, M.B., Gaudy-Marqueste, C., Gogas, H., Grob, J.J., Guckenberger, M., Haanen, J., Hayes, A.J., Hoeller, C., Lebbé, C., Lugowska, I., Mandalà, M., Márquez-Rodas, I., Nathan, P., Neyns, B., Olofsson Bagge, R., Puig, S., Rutkowski, P., Schilling, B., Sondak, V.K., Tawbi, H., Testori, A., Keilholz, U.

Volltext

Real-world multicentre observational study of effectiveness and toxicity in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab von Faoro, L, Salizzato, V, Coppola, M, Carpanese, D, Fabozzi, A, Tondulli, L, Marconcini, R, Spagnolo, F, Del Bianco, P, Chiarion-Sileni, V, Piccin, L

Volltext

Electrochemotherapy for disseminated superficial metastases from malignant melanoma von Campana, L. G., Valpione, S., Mocellin, S., Sundararajan, R., Granziera, E., Sartore, L., Chiarion-Sileni, V., Rossi, C. R.

Volltext

Small molecules and targeted therapies in distant metastatic disease von Hersey, P., Bastholt, L., Chiarion-Sileni, V., Cinat, G., Dummer, R., Eggermont, A. M. M., Espinosa, E., Hauschild, A., Quirt, I., Robert, C., Schadendorf, D.

Volltext

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study von Long, G.V., Flaherty, K.T., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Chiarion-Sileni, V., Lebbe, C., Mandalà, M., Millward, M., Arance, A., Bondarenko, I., Haanen, J.B.A.G., Hansson, J., Utikal, J., Ferraresi, V., Mohr, P., Probachai, V., Schadendorf, D., Nathan, P., Robert, C., Ribas, A., Davies, M.A., Lane, S.R., Legos, J.J., Mookerjee, B., Grob, J.-J.

Volltext

Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study von O'Day, S.J., Maio, M., Chiarion-Sileni, V., Gajewski, T.F., Pehamberger, H., Bondarenko, I.N., Queirolo, P., Lundgren, L., Mikhailov, S., Roman, L., Verschraegen, C., Humphrey, R., Ibrahim, R., de Pril, V., Hoos, A., Wolchok, J.D.

Volltext

Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma von Maio, M., Danielli, R., Chiarion-Sileni, V., Pigozzo, J., Parmiani, G., Ridolfi, R., De Rosa, F., Del Vecchio, M., Di Guardo, L., Queirolo, P., Picasso, V., Marchetti, P., De Galitiis, F., Mandalà, M., Guida, M., Simeone, E., Ascierto, P.A.

Volltext

Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up von Amaral, T., Ottaviano, M., Arance, A., Blank, C., Chiarion-Sileni, V., Donia, M., Dummer, R., Garbe, C., Gershenwald, J.E., Gogas, H., Guckenberger, M., Haanen, J., Hamid, O., Hauschild, A., Höller, C., Lebbé, C., Lee, R.J., Long, G.V., Lorigan, P., Muñoz Couselo, E., Nathan, P., Robert, C., Romano, E., Schadendorf, D., Sondak, V., Suijkerbuijk, K.P.M., van Akkooi, A.C.J., Michelin, O., Ascierto, P.A.

Volltext

Phase II trial of docetaxel, cisplatin and fluorouracil followed by carboplatin and radiotherapy in locally advanced oesophageal cancer von CHIARION-SILENI, V, CORTI, L, RUOL, A, INNOCENTE, R, BOSO, C, DEL BIANCO, P, PIGOZZO, J, MAZZAROTTO, R, TOMASSI, O, ANCONA, E

Volltext

Personalised medicine: Development and external validation of a prognostic model for metastatic melanoma patients treated with ipilimumab von Valpione, S, Martinoli, C, Fava, P, Mocellin, S, Campana, L.G, Quaglino, P, Ferrucci, P.F, Pigozzo, J, Astrua, C, Testori, A, Chiarion-Sileni, V

Volltext

Surgery and radiotherapy in the treatment of cutaneous melanoma von Testori, A., Rutkowski, P., Marsden, J., Bastholt, L., Chiarion-Sileni, V., Hauschild, A., Eggermont, A. M. M.

Volltext

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study von Long, G.V., Flaherty, K.T., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Chiarion-Sileni, V., Lebbe, C., Mandalá, M., Millward, M., Arance, A., Bondarenko, I., Haanen, J.B.A.G., Hansson, J., Utikal, J., Ferraresi, V., Mohr, P., Probachai, V., Schadendorf, D., Nathan, P., Robert, C., Ribas, A., Davies, M.A., Lane, S.R., Legos, J.J., Mookerjee, B., Grob, J.-J.

Volltext

LBA3 Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: Efficacy and safety results from the KEYNOTE-716 double-blind phase III trial von Luke, J.J., Rutkowski, P., Queirolo, P., Del Vecchio, M., Mackiewicz, J., Chiarion Sileni, V., de la Cruz Merino, L., Khattak, M.A., Schadendorf, D., Long, G.V., Ascierto, P.A., Mandala, M., De Galitiis, F., Sondak, V., Scolyer, R.A., Kirkwood, J.M., Chen, K., Ibrahim, N., Ahsan, S., Eggermont, A.M.M.

Volltext

Clinical implication of tumor-associated and immunological parameters in melanoma patients treated with ipilimumab von Damuzzo, V., Solito, S., Pinton, L., Carrozzo, E., Valpione, S., Pigozzo, J., Arboretti Giancristofaro, R., Chiarion-Sileni, V., Mandruzzato, S.

Volltext

Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy von Chiarion-Sileni, V, Pigozzo, J, Ascierto, P A, Simeone, E, Maio, M, Calabrò, L, Marchetti, P, De Galitiis, F, Testori, A, Ferrucci, P F, Queirolo, P, Spagnolo, F, Quaglino, P, Carnevale Schianca, F, Mandalà, M, Di Guardo, L, Del Vecchio, M

Volltext

Updated relapse-free survival (RFS) and biomarker analysis in the COMBI-AD trial of adjuvant dabrafenib + trametinib (D + T) in patients (pts) with resected BRAF V600–mutant stage... von Long, G.V., Hauschild, A., Santinami, M., Atkinson, V.G., Mandala, M., Chiarion-Sileni, V., Larkin, J., Robert, C., Schadendorf, D., Dasgupta, K., Shilkrut, M., Garrett, J., Brase, J.C., Kefford, R., Kirkwood, J.M., Dummer, R.

Volltext

Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine von Grob, J.-J., Amonkar, M.M., Martin-Algarra, S., Demidov, L.V., Goodman, V., Grotzinger, K., Haney, P., Kämpgen, E., Karaszewska, B., Mauch, C., Miller, W.H., Millward, M., Mirakhur, B., Rutkowski, P., Chiarion-Sileni, V., Swann, S., Hauschild, A.

Volltext

Report from the Melanoma Independent Board First Melanoma MIB Conference, 21-22 October 2013 von Testori, A, Ascierto, P, Chiarion Sileni, V, De Lorenzo, F, Pelicci, Pg, Rossi, Cr

Volltext

Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer. A multicenter, randomized phase III trial von Paccagnella, Adriano, Favaretto, A., Oniga, F., Barbieri, F., Ceresoli, G., Torri, W., Villa, E., Verusio, C., Cetto, G.L., Santo, A., De Pangher, V., Artioli, F., Cacciani, G.C., Parodi, G., Soresi, F., Ghi, M.G., Morabito, A., Biason, R., Giusto, M., Mosconi, P., Chiarion Sileni, V.

Volltext